Most hospitals consider a patient 'managed' once medication is prescribed. We consider it managed only when the patient's HbA1c is below target, complications are prevented, and medication is being reduced — not increased.
"Our mission is for every patient who walks through our doors to achieve meaningful control of their diabetes — not just have it managed with increasing doses of medication. We define success as: HbA1c below 7.0, stable or reducing medication, and zero preventable complications. Nothing less."
Success means achieving target, not just starting treatment. A prescription without outcome tracking is not success — it is deferred responsibility.
The single most important number in diabetes management. Every patient in our programme has a committed HbA1c target from day one.
Our goal is the minimum effective medication, not the maximum tolerated. As patients improve, doses come down — not up. Our data proves it.
India's national HbA1c control rate sits below 20%. We treat this as a system failure, not a patient failure. Here is how most care falls short — and how we address every gap.
A structured, outcome-driven journey from initial control to lifelong maintenance. Every phase has a clear goal, a clear timeline, and a committed outcome target.
For patients with specific profiles, we offer dedicated tracks that run alongside or within the core programme — each with its own protocol, team, and outcome target.
For patients with early Type 2 diabetes — HbA1c 6.5–8.5, diabetes under 10 years, not yet on insulin. The goal is not just control but complete medication-free normal glucose. Combines intensive dietary intervention (calorie restriction protocol), structured exercise, and metabolic monitoring.
For patients with HbA1c above 9.0 or significant obesity (BMI above 30). Mounjaro, Wegovy, or Ozempic is added to the Phase 1 protocol, accelerating glucose control and weight reduction simultaneously. Managed by Dr. Bhansali — one of India's highest-volume GLP-1 prescribers.
Added automatically to all Phase 2 and Phase 3 patients. Annual comprehensive foot check by our specialist team: monofilament sensory test, ankle-brachial index, neuropathy assessment, footwear review, and patient education. For patients with existing foot problems, escalation to our Diabetic Foot Treatment service.
No other hospital in North India publishes its diabetes outcomes. We do. Because we believe accountability drives improvement — and our patients deserve to know what they're investing in.
All outcomes tracked in our proprietary patient database. Aggregate data reviewed quarterly by Dr. Bhansali and the clinical team. Available for clinical review on request.
We know we haven't reached 100% yet. Our current Phase 1 success rate is 80–85%. The 15–20% who don't achieve target in 12 weeks have longer-standing diabetes, advanced beta cell failure, or complex comorbidities. We haven't given up on them — they stay in the programme with extended timelines and escalated interventions. Our public commitment: every year, we aim to close the gap.
No other hospital in North India publishes its diabetes outcomes. We do. We report our numbers because we believe accountability drives improvement. When our team reviews quarterly data and sees that 1 in 6 patients did not reach target, it drives protocol changes, new interventions, and harder conversations about what more we can do.
Everything you need to know before joining the programme.
Phase 1 Enrolment — ₹35,000 for 12 weeks. Includes all consultations, CGM rental, diet plans, lab monitoring, and WhatsApp support. Led by Dr. Anil Bhansali.